Search Results - "Mañé, J.M."

Reversible liver toxicity with adjuvant trastuzumab for localized breast cancer by Muñoz, A., Carrera, S., Ferreiro, J., Ruiz de Lobera, A., Mañé, J.M., López-Vivanco, G.

Get full text

9126 Bi-weekly paclitaxel-gemcitabine in patients with small-cell lung cancer resistant to previous platinum and etoposide-based chemotherapy by Bueno, A. Martinez, Rubio, X. Mielgo, Ovejas, E. Iruarrizaga, Carrera, S. Sergio, de Lobera Martinez, A. Ruiz, Cornejo, R. Casas, Rodriguez, R. Fernandez, Quintana, J. Ferreiro, Quintanilla, D. Ballesteros, Martinez, J.M. Mañé

Get full text

Distal ischemic changes related to combination chemotherapy with cisplatin and gemcitabine: Description of four cases by Barceló, R., López-Vivanco, G., Mañé, J. M., Rubio, I., Muñoz, A., Fernández, R.

Get full text

Preoperative chemo-radiotherapy (CHRT) in esophageal carcinoma (EC): response, toxicity and survival analysis by Vivanco, G.López, Muñoz, G., Rubio, I., Barceló, J.R., Fernández, R., Mañé, J.M., Fuente, N., Abón, G.

Get full text

Gemcitabine and vascular toxicity by Muñoz, A, Mañé, J.M, Rubio, I, Fernández, R, Fuente, N, Barceló, R, Vivanco, G.López

Get full text

Treatment of glioblastoma multiforme (GBM) with teniposide (VM26) and Iomustine (CCNU) followed by radiotherapy by Mañé, J.M., Barceló, J.R., Rubio, I., Fernández, R., Fuente, N., Abón, G., Muñoz, A., López-Vivanco, G.

Get full text

Adjuvant 5-FU based therapy for colorectal cancer by Muñoz, A., Rubio, I., Mañé, J.M., Barceló, J.R., Fernández, R., Abón, G., Fuente, N., López-Vivanco, G.

Get full text

Second line treatment with irinotecan (CPT11) in patients (pts) with advanced colo-rectal carcinoma (ACRC) resistant to 5FU by Barceló, J.R., Rubio, I., Fernández, R., Mañé, J.M., Muñoz, A., Abón, G., Fuente, N., López-Vivanco, G.

Get full text

Cancer diagnosis disclosure in a Spanish hospital by Estapé, J, Palombo, H, Hernández, E, Daniels, M, Estapé, T, Grau, J J, Viñolas, N, Mañé, J M

“…At the Clinic Hospital in Barcelona, Spain, 167 cancer patients and 380 hospital health care workers were interviewed about cancer diagnosis disclosure. Only…”
Get more information

P240 - Atezolizumab (Atz) outcomes in platinum pretreated advanced urothelial carcinoma patients: a retrospective review of a 5-year period at a tertiary center by Iruarrizaga Ovejas, E., Novo Sukia, E., Iza Rodriguez, E., Mane Martinez, J.M., Fernandez Rodriguez, R.

Get full text

Atezolizumab (Atz) outcomes in platinum pretreated advanced urothelial carcinoma patients: a retrospective review of a 5-year period at a tertiary center by Iruarrizaga Ovejas, E., Novo Sukia, E., Iza Rodriguez, E., Mane Martinez, J.M., Fernandez Rodriguez, R.

Get full text

Tumor lysis syndrome in a multiple myeloma treated with thalidomide by Fuente, N., Mañe, J. M., Barcelo, R., Muñoz, A., Perez-Hoyos, T., Lopez-Vivanco, G.

Get full text

Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study by Felip, E., Rosell, R., Domine, M., Santomé, L., Garrido, P., Font, A., Carrato, A., Terrasa, J., Vadell, C., Mañe, J. M., Baselga, J.

“…Background: Poor survival rates in extensive-stage small-cell lung cancer (SCLC) patients prompted us to evaluate a sequential dose-dense schedule of…”
Get full text

CYFRA 21-1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels by Molina, R, Agusti, C, Mañe, J M, Filella, X, Jo, J, Joseph, J, Giménez, N, Estapé, J, Ballesta, A M

“…CYFRA 21-1, CEA, CA 125, SCC and NSE serum levels were determined in 50 healthy subjects and in 189 patients with primary lung cancer (101 with locoregional…”
Get more information